BeOne Medicines Ltd ADR
BeOne Medicines Ltd ADR (ONC) Straddle
ONC straddle scan found 77 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 50.0%.
Read more
Trading a ONC straddle lets you take a pure volatility position on BeOne Medicines Ltd ADR without committing to a direction. BeOne Medicines Ltd ADR's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate ONC straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on ONC profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when BeOne Medicines Ltd ADR stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the ONC straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China.
The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the ONC straddle is the cleanest expression of that view. Our scanner prices every ONC straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a ONC straddle into a catalyst or short a ONC straddle to harvest decay, the options straddle setups that matter are all in one place.
| Feb 19, 2027 | 540.00 | $191.60 | 154 | 1% | 50.0% | $731.60 | $348.40 | 0 |
| Feb 19, 2027 | 520.00 | $172.10 | 154 | 1% | 49.7% | $692.10 | $347.90 | 0 |
| Feb 19, 2027 | 500.00 | $153.50 | 154 | 1% | 49.1% | $653.50 | $346.50 | 0 |
| Feb 19, 2027 | 490.00 | $144.40 | 154 | 1% | 48.7% | $634.40 | $345.60 | 0 |
| Nov 20, 2026 | 460.00 | $111.80 | 63 | 1% | 48.6% | $571.80 | $348.20 | 0 |
| Nov 20, 2026 | 440.00 | $92.25 | 63 | 1% | 48.4% | $532.25 | $347.75 | 0 |
| Feb 19, 2027 | 480.00 | $135.75 | 154 | 1% | 48.2% | $615.75 | $344.25 | 0 |
| Nov 20, 2026 | 430.00 | $82.95 | 63 | 1% | 47.9% | $512.95 | $347.05 | 0 |
| Feb 19, 2027 | 470.00 | $127.60 | 154 | 1% | 47.4% | $597.60 | $342.40 | 0 |
| Feb 19, 2027 | 460.00 | $119.30 | 154 | 1% | 46.8% | $579.30 | $340.70 | 0 |
As of September 18, 2026
Find the right straddle before volatility moves
Track ONC straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→